PROM1 and hepatocellular carcinoma: Another phase II clinical trial (NCT02541370) using anti-CD133 CAR-T cells in hepatocellular carcinoma resulted in a median progression-free survival (PFS) of 6.8 months and overall survival of 12 months; however, only one patient achieved partial response [265].